Alecensa (alectinib) vs Exkivity (mobocertinib)
Alecensa (alectinib) vs Exkivity (mobocertinib)
Alecensa (alectinib) and Exkivity (mobocertinib) are both targeted therapies used to treat non-small cell lung cancer (NSCLC), but they are indicated for different genetic alterations. Alecensa is specifically designed to inhibit the activity of anaplastic lymphoma kinase (ALK) and is used in patients with ALK-positive NSCLC. In contrast, Exkivity is a tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) exon 20 insertion mutations and is used in patients with NSCLC harboring these specific mutations. When deciding between the two, it is crucial to have your tumor genetically tested to determine if it has the ALK mutation or the EGFR exon 20 insertion mutation, as this will directly influence which medication is appropriate for your condition.
Difference between Alecensa and Exkivity
| Metric | Alecensa (alectinib) | Exkivity (mobocertinib) |
|---|---|---|
| Generic name | alectinib | mobocertinib |
| Indications | ALK-positive metastatic non-small cell lung cancer (NSCLC) | EGFR Exon20 insertion mutation positive metastatic NSCLC |
| Mechanism of action | ALK inhibitor | EGFR inhibitor |
| Brand names | Alecensa | Exkivity |
| Administrative route | Oral | Oral |
| Side effects | Fatigue, constipation, edema, myalgia, anemia | Diarrhea, rash, nausea, vomiting, decreased appetite |
| Contraindications | Hypersensitivity to alectinib or any excipients | Hypersensitivity to mobocertinib or any excipients |
| Drug class | Tyrosine kinase inhibitor | Tyrosine kinase inhibitor |
| Manufacturer | Genentech (a member of the Roche Group) | Takeda Oncology |
Efficacy
Alecensa (Alectinib) Efficacy in Lung Cancer
Alecensa (alectinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations known as ALK (anaplastic lymphoma kinase) rearrangements. Clinical trials have demonstrated that alectinib is highly effective in patients with ALK-positive NSCLC. In a pivotal phase III study known as the ALEX trial, alectinib significantly improved progression-free survival compared to crizotinib, another ALK inhibitor, in previously untreated patients. Alectinib has also shown high central nervous system (CNS) activity, effectively controlling brain metastases, which are common in ALK-positive NSCLC patients.
Further studies have indicated that alectinib has a favorable safety profile and is generally well-tolerated by patients. Its efficacy extends to those who have progressed on or are intolerant to crizotinib, offering a valuable treatment option for patients with advanced ALK-positive NSCLC. The durability of response and overall survival benefits are significant, making alectinib a preferred first-line therapy for this subset of lung cancer patients.
Exkivity (Mobocertinib) Efficacy in Lung Cancer
Exkivity (mobocertinib) is an oral medication specifically designed for the treatment of adult patients with metastatic NSCLC harboring EGFR exon 20 insertion mutations, which are resistant to conventional EGFR tyrosine kinase inhibitors. Mobocertinib's efficacy was evaluated in a multicohort, multicenter, open-label, non-randomized phase 1/2 trial. The results showed a meaningful response rate and duration of response in patients with EGFR exon 20 insertion-positive metastatic NSCLC who had been previously treated with platinum-based chemotherapy.
The clinical trial data for mobocertinib indicate that it fills a significant unmet need for patients with this challenging type of lung cancer mutation. The drug has demonstrated a reduction in tumor size and prolonged disease control. While the treatment landscape for EGFR-mutated NSCLC has been evolving, mobocertinib provides a targeted approach for a subset of patients who previously had limited options. Its approval by regulatory agencies underscores the importance of precision medicine in the management of lung cancer.
Regulatory Agency Approvals
Alecensa
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Exkivity
-
Food and Drug Administration (FDA), USA
Access Alecensa or Exkivity today
If Alecensa or Exkivity are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us